of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Regulation FD Disclosure. On June 30, 2026, the Company issued a press release announcing the Private Placement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any…

Unregistered Sales of Equity Securities. To the extent required by Form 8-K, the disclosures in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On June 30, 2026, Pyxis Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers an aggregate of (i) 19,…

of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Director — Dr. Sullivan: Dr. Sullivan resigned from the Board of Directors and separated from the Company under a Separation Agreement.

Results of Operations and Financial Condition. On March 23, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the full year ended December 31, 2025 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

CEO — Dr. Lara Sullivan, M.D.: Dr. Lara Sullivan ceased serving as CEO and was replaced by Tom Civik as Interim Chief Executive Officer.

Other Events. The Company today announced positive preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM), in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The cutoff for all data reported below is as of November 3, 2025. Monotherapy The…

of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Chief Financial Officer and Chief Operating Officer — Pamela Connealy: Ms. Connealy retired from the Company and was succeeded by Jitendra Wadhane as Principal Financial Officer.

Results of Operations and Financial Condition. On May 15, 2025, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the Quarter ended March 31, 2025 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On March 18, 2025, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the full year ended December 31, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Chief Medical Officer — Ken Kobayashi, M.D., F.A.C.P: Ken Kobayashi is stepping down from his position as Chief Medical Officer, and Lara S. Sullivan will assume the role in addition to her current roles.

Other Events. On February 26, 2025, Pyxis Oncology, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-…

Other Events. On February 4, 2025, Pyxis Oncology, Inc. issued a press release announcing the initiation of a Phase 1/2 combination trial, PYX-201-102, with PYX-201 and Merck’s Keytruda® (pembrolizumab) in multiple solid tumors. In addition, the Part 2 monotherapy expansion cohorts of the ongoing Phase 1 PYX-201-101 study have begun enrolling patients. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. KEYTRUDA ® is a registered trademark of Merck Sha…

Other Events. On December 19, 2024, Pyxis Oncology, Inc. (the “Company”) announced a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201, a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix. A copy of the press release is attached hereto as Exhibit 99.1 to this Curre…

Results of Operations and Financial Condition. On November 12, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of t…

Results of Operations and Financial Condition. On August 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Secu…

Director — Michael A. Metzger: Appointment of Michael A. Metzger as a new independent director.

Results of Operations and Financial Condition. On May 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securi…

Other Events. On August 23, 2023, Pyxis Oncology, Inc. (the “Company”) filed a Current Report on Form 8-K (as amended by Form 8-K/A filed on October 27, 2023) to report, among other things, the completion of its acquisition of Apexigen, Inc., a Delaware corporation (“Apexigen”) on August 23, 2023, contemplated by that certain Agreement and Plan of Merger, dated as of May 23, 2023 (the “Merger Agreement”), with Apexigen, and Ascent Merger Sub Corp., a Delaware corporation and a wholly owned su…

Other Events. On March 27, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing that the Company entered into an agreement with Novartis Technology LLC (“Novartis”) for the sale of its rights to royalties from the commercialization of Beovu® (brolucizumab-dbll) and another asset for a one-time cash payment of $8 million. Additionally, all royalties previously received by Apexigen, Inc. (“Apexigen”) and the Company from Novartis will be free from any reclaim rights. In…

Results of Operations and Financial Condition. On March 21, 2024, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the full year ended December 31, 2023 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.